Felix Kesselring
Bratschi Rechtsanwälte
Referent:innen
Dr Carsten Meininghaus
DSM Nutritional Products
Dr Ina Bach
Dr. Bach
Dr Ulrich Kissel
European QP Association (EQPA), KisselPharmaConsulting
Dr Karin Hofstetter
BioAtrium
Jette Petersen
F. Hoffmann-La Roche
Zielsetzung
- Learn and discuss the special tasks and responsibilities of the Responsible Person (RP) in Switzerland (Qualified Person/QP according EU legislation).
- Exchange opinions and convey possible solutions to problems addressed in case studies and workshops.
- Benefit from the speakers’ experience in industry, authority and legal advice.
Under the Agreement of 21 June 1999 between the Swiss Confederation and the European Community (Mutual Recognition Agreement, MRA), Switzerland obliged to comply with the EU-GMP regulation. This means that the GMP requirements of Directive 2001/83 / EC (in particular Article 46. to 52 for the QP) also apply in Switzerland.
The requirements for a Responsible Person (“Fachtechnisch Verantwortliche Person” in the German speaking part) are described in art. 5, art. 10, art. 14 and art. 15 of the Ordinance on Establishment Licences. With its signature, the RP confirms that a batch meets the specifications and has been manufactured in a GMP-compliant system. This system- related statement is considerably more comprehensive than a batch-related confirmation, which aims solely to comply with the specifications. Therefore the duties and responsibilities can be rather extensive.
On 1 January 2019, the revised Therapeutic Products Act (HMG 2) and amendments to the ordinances (Therapeutic Products Ordinance Package IV) came into force - with some interesting alterations.
The requirements for a Responsible Person (“Fachtechnisch Verantwortliche Person” in the German speaking part) are described in art. 5, art. 10, art. 14 and art. 15 of the Ordinance on Establishment Licences. With its signature, the RP confirms that a batch meets the specifications and has been manufactured in a GMP-compliant system. This system- related statement is considerably more comprehensive than a batch-related confirmation, which aims solely to comply with the specifications. Therefore the duties and responsibilities can be rather extensive.
On 1 January 2019, the revised Therapeutic Products Act (HMG 2) and amendments to the ordinances (Therapeutic Products Ordinance Package IV) came into force - with some interesting alterations.
Hintergrund
Under the Agreement of 21 June 1999 between the Swiss Confederation and the European Community (Mutual Recognition Agreement, MRA), Switzerland obliged to comply with the EUGMP regulation. This means that the GMP requirements of Directive 2001/83 / EC (in particular Article 46. to 52 for the QP) also apply in Switzerland.
The requirements for a Responsible Person (“Fachtechnisch Verantwortliche Person” in the German speaking part) are described in art. 5, art. 10, art. 14 and art. 15 of the Ordinance on Establishment Licences. With its signature, the RP confirms that a batch meets the specifications and has been manufactured in a GMP-compliant system. This system-related statement is considerably more comprehensive than a batch-related confirmation, which aims solely to comply with the specifications. Therefore the duties and responsibilities can be rather extensive.
On 1 January 2019, the revised Therapeutic Products Act (HMG 2) and amendments to the ordinances (Therapeutic Products Ordinance Package IV) came into force - with some interesting alterations.
The requirements for a Responsible Person (“Fachtechnisch Verantwortliche Person” in the German speaking part) are described in art. 5, art. 10, art. 14 and art. 15 of the Ordinance on Establishment Licences. With its signature, the RP confirms that a batch meets the specifications and has been manufactured in a GMP-compliant system. This system-related statement is considerably more comprehensive than a batch-related confirmation, which aims solely to comply with the specifications. Therefore the duties and responsibilities can be rather extensive.
On 1 January 2019, the revised Therapeutic Products Act (HMG 2) and amendments to the ordinances (Therapeutic Products Ordinance Package IV) came into force - with some interesting alterations.
Zielgruppe
Responsible Persons/ RPs for batch certification and release and Executives and Managers who want to get an overview on the duties and responsibilities of the RP.
Date & Venue
Date
04/05 March 2026
Wednesday, 04 March 2026, 9.30h – 17.30h
(Registration and coffee 9.00h – 9.30h)
Thursday, 05 March 2026, 8.30h – 16.00h
Wednesday, 04 March 2026, 9.30h – 17.30h
(Registration and coffee 9.00h – 9.30h)
Thursday, 05 March 2026, 8.30h – 16.00h
Venue
Hotel Ambassador & Spa
Seftigenstrasse 99
3007 Bern
Switzerland
Tel.: +41 (0)31 370 99 99
Fax: +41 (0)31 371 41 17
E-Mail: ambassador@fhotels.ch
Programm
Gesamtes Programm als PDF herunterladen
EU Regulations and their Implementation in Switzerland
- Directive 2001/83/EG and the Qualified Person
- Mutual Recognition Agreement
- Ordinance on Establishment Licences OEL (AMBV, OAMéd)
Role and Tasks of the Responsible Person
- The role in the company and the organisation Chart
- Batch certification and release
- Cross-boarder activities
- Personal duties and responsibilities
- Delegation
- Deputies
- Internal delimitation of responsibilities
- Contract RPs
Outsourcing: What the RP should know about assuring Product Quality
- Compliance with the registration
- Compliance with GMP
- Audits and supplier qualification
- Necessary batch documentation
- Product Quality Review (PQR)
- Delimitation of Responsibilities in the supply Chain
- Quality (Technical) Agreement
INTERACTIVE SESSION
Certification and Batch Release: to certify or not, that’s the question!
Decision making based on real examples
Certification and Batch Release: to certify or not, that’s the question!
Decision making based on real examples
The API Supply Chain
- Requirements in Switzerland and the EU
- Responsibilities of the RP
- Questions, challenges and solutions
The GMP/GDP Interface
- Consequences of the Therapeutic Products Act and Amendments to Ordinances
- Storage and transport
- Import and export: particularities
- Cool and cold chain issues
- Supply chain traceability
The Responsible Person’s daily Work: what the RP needs to know about:
- Communication and collaboration with the authorities
- Risk Management
- KPIs
- Management Review
What the Responsible Person needs to know about Investigational Medicinal Products (IMPs)
- The new EU Clinical Trial Regulation and the consequences for Switzerland
- IMP supply to the EU
- IMP transfer in Switzerland
- Labelling
- Named Patient Import
Liability
- Principles of liability
- When will the RP be liable?
- Potential sanctions
- Examples from the real life, case law
INTERACTIVE SESSION
Quality Control and Laboratory: what the RP needs to know
Quality Control and Laboratory: what the RP needs to know
- Responsibilities
- OOS, OOE und OOT
- Fault Analysis
- Statistics
| Regular Fee*: | € 1990,- |
| EU/GMP Inspectorates*: | € 845,- |
| QP Member Discount*: | € 1790,- |
Alle Preise zzgl. MwSt. Wichtige Hinweise zur Umsatzsteuer.
* auch unkompliziert per Kreditkarte bezahlbar
Weitere Termine vor Ort
Weitere Termine vor Ort nicht verfügbar
Weitere Termine online
Weitere Termine online nicht verfügbar
Aufzeichnung nicht verfügbar
Haben Sie noch Fragen?
Wir stehen Ihnen für weitere Auskünfte gerne zur Verfügung.
E-Mail: info@concept-heidelberg.de
Für Lieferanten: Ausstellungs- und Sponsoringmöglichkeiten
Seminarprogramm als PDFTeilnehmerstimmen - das sagen andere über unsere Seminare:
